Cargando…
Estrogen receptor testing and 10-year mortality from breast cancer: A model for determining testing strategy
BACKGROUND: The use of adjuvant tamoxifen therapy in the treatment of estrogen receptor (ER) expressing breast carcinomas represents a major advance in personalized cancer treatment. Because there is no benefit (and indeed there is increased morbidity and mortality) associated with the use of tamoxi...
Autor principal: | Naugler, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352613/ https://www.ncbi.nlm.nih.gov/pubmed/22616031 http://dx.doi.org/10.4103/2153-3539.95452 |
Ejemplares similares
-
Estrogen and Estrogen Receptor Modulators: Potential Therapeutic Strategies for COVID-19 and Breast Cancer
por: Hu, Shuying, et al.
Publicado: (2022) -
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer
por: Glazer, Robert I., et al.
Publicado: (2017) -
Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022) -
Estrogen receptors and breast cancer.
por: Nicholson, R I, et al.
Publicado: (1981) -
Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
por: Dekker, T. J. A., et al.
Publicado: (2015)